Want to see JP:4586 full AI Analyst Report?

Medrx Co., Ltd. (4586) Price & Analysis

0 Followers

4586 Stock Chart & Stats

¥67.00

¥1.00(1.56%)

At close: Jul 30 4:00 PM EDT

¥67.00

¥1.00(1.56%)

Day’s Range― - ―

52-Week Range¥48.00 - ¥225.00

Previous CloseN/A

Volume530.50K

Average Volume (3M)1.05M

Market Cap

¥4.18B

Enterprise Value¥2.13K

Total Cash (Recent Filing)¥1.14B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta1.30

Next Earnings

Nov 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-14.23

Shares Outstanding68,530,600

10 Day Avg. Volume1,202,190

30 Day Avg. Volume1,050,606

Financial Highlights & Ratios

PEG Ratio1.03

Price to Book (P/B)2.83

Price to Sales (P/S)45.31

P/FCF Ratio-5.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross MarginsSustained gross margins near 85–90% across recent years indicate structurally high product-level profitability tied to the firm’s transdermal formulation capabilities. High gross margin provides durable gross cash generation potential as revenue scales, supporting long-term product investment.

Conservative Balance Sheet (zero Debt)A zero-debt capital structure across 2021–2025 reduces solvency and interest-rate risk, giving the company durable financial flexibility to raise capital or execute strategic moves. Low leverage is a multi-month to multi-year advantage while losses persist.

2025 Revenue ReboundA roughly 186% revenue increase in 2025 signals emerging commercial traction or successful product launches. If sustained, this structural demand recovery can leverage the firm’s high gross margins to improve operating leverage and support longer-term revenue growth.

Bears Say

Persistent Negative Operating/ Free Cash FlowConsistent yearly negative operating and free cash flow means the company is not self-funding and must rely on external financing or shareholder capital. Over a 2–6 month horizon this structural cash burn raises financing risk and constrains strategic flexibility.

Very Large Operating And Net LossesExtremely negative net margins (about -732% in 2025) show operating costs far exceed revenue. This indicates structural profitability challenges: even with high gross margins, SG&A/R&D or other expenses overwhelm results and must be restructured for durable profitability.

Negative Returns On EquityPersistently negative ROE over multiple years signals erosion of shareholder value and poor capital efficiency. If losses continue, equity base could be further impaired, reducing long-term investor returns and making future capital raises more dilutive or costly.

4586 FAQ

What was Medrx Co., Ltd.’s price range in the past 12 months?

Medrx Co., Ltd. lowest stock price was ¥48.00 and its highest was ¥225.00 in the past 12 months.

What is Medrx Co., Ltd.’s market cap?

Medrx Co., Ltd.’s market cap is ¥4.18B.

When is Medrx Co., Ltd.’s upcoming earnings report date?

Medrx Co., Ltd.’s upcoming earnings report date is Nov 06, 2026 which is in 54 days.

How were Medrx Co., Ltd.’s earnings last quarter?

Medrx Co., Ltd. released its earnings results on Aug 07, 2026. The company reported -¥5.25 earnings per share for the quarter.

Is Medrx Co., Ltd. overvalued?

According to Wall Street analysts Medrx Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medrx Co., Ltd. pay dividends?

Medrx Co., Ltd. does not currently pay dividends.

What is Medrx Co., Ltd.’s EPS estimate?

Medrx Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medrx Co., Ltd. have?

Medrx Co., Ltd. has 68,530,600 shares outstanding.

What happened to Medrx Co., Ltd.’s price movement after its last earnings report?

Medrx Co., Ltd. reported an EPS of -¥5.25 in its last earnings report. Following the earnings report the stock price went down -4.412%.

Which hedge fund is a major shareholder of Medrx Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4586

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medrx Co., Ltd.

Established in 2002 and headquartered in Higashikagawa, Japan, MedRx Co., Ltd is a pharmaceutical firm focused on developing drug formulations. The company primarily provides pharmaceutical products in Japan that leverage transdermal absorption systems. Their innovation centers on technologies such as the Ionic Liquid Transdermal System (ILTS) and the Nano-sized Colloid Transdermal System (NCTS). MedRx also actively researches the pain-free transdermal delivery of various substances, including vaccines, nucleic acid medicines, and protein medicines. Its diverse product pipeline includes MRX-4TZT, undergoing Phase I clinical trials for spastic paralysis, and MRX-9FLT, also in Phase I, designed to alleviate chronic, cancer-related, and severe pain. Additionally, MRX-7MLL for Alzheimer's disease and MRX-6LDT for chronic pain are both in pre-clinical development. A notable achievement is MRX-5LBT, which has successfully concluded clinical trials for treating postherpetic nerve pain.